LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Iovance Biotherapeutics Inc

Geschlossen

BrancheGesundheitswesen

1.77

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.71

Max

1.78

Schlüsselkennzahlen

By Trading Economics

Einkommen

-38M

-116M

Verkäufe

-24M

49M

EPS

-0.36

Gewinnspanne

-235.51

Angestellte

838

EBITDA

-35M

-110M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+548.31% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-558M

611M

Vorheriger Eröffnungskurs

1.77

Vorheriger Schlusskurs

1.77

Nachrichtenstimmung

By Acuity

50%

50%

166 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Iovance Biotherapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Mai 2025, 20:33 UTC

Akquisitionen, Fusionen, Übernahmen

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

23. Mai 2025, 21:57 UTC

Heiße Aktien

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

23. Mai 2025, 21:15 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23. Mai 2025, 21:04 UTC

Akquisitionen, Fusionen, Übernahmen

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

23. Mai 2025, 20:56 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Salesforce Back in Deal Talks With Informatica -- WSJ

23. Mai 2025, 20:51 UTC

Top News

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

23. Mai 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

23. Mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. Mai 2025, 20:41 UTC

Top News

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

23. Mai 2025, 20:28 UTC

Top News

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

23. Mai 2025, 20:06 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

23. Mai 2025, 20:06 UTC

Akquisitionen, Fusionen, Übernahmen

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

23. Mai 2025, 19:50 UTC

Top News

Trump's Tariffs: Where Things Stand -- 16th Update

23. Mai 2025, 19:28 UTC

Akquisitionen, Fusionen, Übernahmen

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

23. Mai 2025, 19:28 UTC

Akquisitionen, Fusionen, Übernahmen

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

23. Mai 2025, 19:27 UTC

Akquisitionen, Fusionen, Übernahmen

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

23. Mai 2025, 19:20 UTC

Market Talk

Crude Futures Post Modest Weekly Losses -- Market Talk

23. Mai 2025, 19:18 UTC

Market Talk

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

23. Mai 2025, 18:57 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23. Mai 2025, 18:54 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

23. Mai 2025, 18:53 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

23. Mai 2025, 18:52 UTC

Akquisitionen, Fusionen, Übernahmen

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

23. Mai 2025, 18:13 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

23. Mai 2025, 18:13 UTC

Market Talk

Gold Trades Higher on Reminder of Risk -- Market Talk

23. Mai 2025, 18:00 UTC

Top News

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

23. Mai 2025, 17:51 UTC

Market Talk
Ergebnisse

Workday Sees Higher Bar for Guidance -- Market Talk

23. Mai 2025, 17:42 UTC

Top News

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

23. Mai 2025, 17:39 UTC

Market Talk

U.S. Oil Rig Count Falls to Lowest Level Since November 2021 -- Market Talk

23. Mai 2025, 17:07 UTC

Top News

Trump's Tariffs: Where Things Stand -- 15th Update

23. Mai 2025, 17:04 UTC

Market Talk
Ergebnisse

Workday Appears to Have Upside Potential on Conservative Outlook -- Market Talk

Peer-Vergleich

Kursveränderung

Iovance Biotherapeutics Inc Prognose

Kursziel

By TipRanks

548.31% Vorteil

12-Monats-Prognose

Durchschnitt 11.54 USD  548.31%

Hoch 25 USD

Tief 2 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Iovance Biotherapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

15 ratings

9

Buy

6

Halten

0

Sell

Technischer Score

By Trading Central

3.0208 / 3.5Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

166 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.